Adc Therapeutics SA (NYSE: ADCT): Stock Forecast For 2025 Sees A An Incline Of 44.22%

EVTL

In the last trading session, 1.04 million shares of the Adc Therapeutics SA (NYSE:ADCT) were traded, and its beta was 1.92. Most recently the company’s share price was $2.87, and it changed around $0.17 or 6.30% from the last close, which brings the market valuation of the company to $284.64M. ADCT currently trades at a discount to its 52-week high of $4.13, offering almost -43.9% off that amount. The share price’s 52-week low was $1.05, which indicates that the current value has risen by an impressive 63.41% since then. We note from Adc Therapeutics SA’s average daily trading volume that its 10-day average is 1.01 million shares, with the 3-month average coming to 676.01K.

Adc Therapeutics SA stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ADCT as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight.

Adc Therapeutics SA (NYSE:ADCT) trade information

Instantly ADCT has showed a green trend with a performance of 6.30% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.98 on recent trading dayincreased the stock’s daily price by 3.69%. The company’s shares are currently down -6.21% year-to-date, but still up 7.09% over the last five days. On the other hand, Adc Therapeutics SA (NYSE:ADCT) is -16.57% down in the 30-day period. We can see from the shorts that 4.53 million shares have been sold at a short interest cover period of 4.89 day(s).

The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 64.12% from its current value. Analyst projections state that ADCT is forecast to be at a low of $7 and a high of $13.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.38%. Adc Therapeutics SA earnings are expected to increase by 8.89% in 2025, but the outlook is positive 16.36% per year for the next five years.

ADCT Dividends

Adc Therapeutics SA’s next quarterly earnings report is expected to be released on 2025-May-14.

Adc Therapeutics SA (NYSE:ADCT)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 21.59% of Adc Therapeutics SA shares, and 67.58% of them are in the hands of institutional investors. The stock currently has a share float of 86.19%. Adc Therapeutics SA stock is held by 115.0 institutions, with REDMILE GROUP, LLC being the largest institutional investor. By 2024-06-30, it held 15.9568% of the shares, which is about 15.27 million shares worth $48.25 million.

PROSIGHT MANAGEMENT, LP, with 10.0009% or 9.57 million shares worth $30.24 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund were the top two Mutual Funds as of May 31, 2025 . The former held 1.93 shares worth $5.53 million, making up 1.94% of all outstanding shares. On the other hand, Fidelity Salem Street Trust-Fidelity Small Cap Index Fund held roughly 821.09 shares worth around $2.36 million, which represents about 0.83% of the total shares outstanding.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.